| Research on new anti-influenza drug baloxavir marboxil |
| Click here to download the full text |
| Citation of this paper:TAO Jia-jia, LYU Qian-zhou, LI Xiao-yu, DAI Pei-fang, YE Yan-rong, SHEN Yun*.Research on new anti-influenza drug baloxavir marboxil[J].Chinese Journal of Clinical Medicine,2019,26(2):308-311 |
| Hits: 2279 |
| Download times: 779 |
|
| Abstract:Baloxavir marboxil is a new anti-influenza drug developed by Shionogi in Japan. It was launched in Japan in February 2018 for the treatment of influenza caused by influenza A and B viruses. Compared with other anti-influenza drugs, baloxavir marboxil has a unique anti-viral mechanism, requiring only one oral dose at a time, with fewer side effects and good patient compliance. In this review, the mechanism of action, pharmacokinetics, pharmacodynamics, clinical trials, and so on of this medicine were discussed. |
| keywords:anti-influenza drugs baloxavir marboxil RNA polymerase cap-dependent endonuclease inhibitor pharmacodynamics pharmacokinetics clinical trials |
| HTML View Full Text View/Add Comment Download reader |
|
|
|